OmniLytics, Incorporated is a biotech company that is focused on developing safe, natural solutions for infectious disease and pest control.

OmniLytics is located in Salt Lake City, Utah with official presence in Honduras, Ecuador, and El Salvador. With emphasis on bacteriophage technology, OmniLytics is pioneering research and development of bacteriophage solutions for pathogen control in the agricultural, food & water, industrial, pharmaceutical, and defense markets.

OmniLytics’ proprietary formulas and processes optimize the use of natural bacteriophage for commercial applications. Bacteriophage solutions are natural, environmentally friendly, safe and effective. OmniLytics is primarily a research and development entity and derives its revenue from the sale of its products directly into certain markets or licensing agreements with its business units (subsidiaries) and strategic partners.

OmniLytics’ historical background dates back to 1954 and includes expansive research, development, knowledge, and expertise using natural products to control dangerous pathogens in a variety of market segments; although the majority of the work over the last ten years has focused on agricultural diseases. As a result of this work, the company has developed several economical and effective products to control destructive plant and animal bacterial diseases that have become resistant to traditional antimicrobial agents.

OmniLytics’ products are made using bacteriophage mixtures. Bacteriophage, or “phage”, are viruses that attack only bacteria. Phage are very specific and only kill a particular species of bacteria. Unlike antibiotics and other chemicals, they will not kill other “good” bacteria, beneficial micro flora or fauna, and have no negative impact on other forms of life or the environment. As a result, the company’s products provide a clean alternative to synthetically produced chemicals that leave behind toxic residues that can adversely affect human health and the environment.

Bacterial viruses were discovered independently by Frederick Twort in 1915 and Felix
d’ Herelle in 1917. At that time, not knowing what had caused the “clear spots” or “lyses” of bacterial colonies, d’ Herelle, a French–Canadian, designated the phenomenon “bacteriophage” which is translated “bacteria-eaters”. During the following two decades bacteriophage were proved to be viruses that attack only bacteria. d’ Herelle’s label and its diminutive version, phage, have become universally accepted by the scientific community and are synonymous with bacterial virus.

Over the past several decades, a major health and agricultural crisis has developed due
to the overuse and misuse of common antibiotics and chemicals as dangerous bacterial pathogens have now become resistant to many of the traditional antimicrobials. Multiple-drug resistance of bacterial pathogens is an increasing problem, especially in clinical environments. Many in the healthcare community believe this to be one of the greatest challenges in treating nosocomial (hospital) infections. This has become a most serious public health and economic threat for the new millennium.

OmniLytics believes phage therapy will be part of a fast growing revolution in determining how patients and crops will be safely and reliably treated in the future.